U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma

Sep.21.2021

R & D

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma

　This material is intended to notify the press release issued on September 20 (local time) by Bristol Myers Squibb, our license partner for Opdivo.
　Please click https://www.bms.com/media/press-releases.html for the original press release.

Back to List